0001668397-26-000019
SEC filingMedpace delivered accelerating revenue growth and robust cash generation in Q1 2026, with net income expansion moderated by a higher tax rate from reduced excess tax benefits on share-based compensation.
Medpace's revenue rose 26.5% to $706.6 million in Q1 2026 from $558.6 million a year ago, reflecting stronger new business volume and task order execution. As noted in management discussion, period-to-period changes arise primarily from these drivers alongside project cancellations, which fluctuate due to customer correspondence timing and study-specific factors, plus shifts in active studies by therapeutic area or lifecycle stage. This dynamic underscores the CRO business's sensitivity to pipeline momentum, enabling revenue scalability as service activities expand without proportional cost pressures.
Operating income climbed 24.6% to $141.5 million, delivering a 20.0% margin on higher revenue. The increase stemmed from elevated reimbursed out-of-pocket expenses and personnel investments to support growing service demands, as highlighted by management. This leverage demonstrates operational efficiency in a clinical trial environment where direct pass-through costs align with billings, preserving margins amid scaling.
Net income advanced 8.1% to $123.9 million, trailing revenue and operating gains due to a higher effective tax rate. Management attributes this primarily to reduced excess tax benefits from share-based compensation versus prior year, coupled with elevated pre-tax income driving a larger provision. Diluted EPS nonetheless rose 16.6% to $4.28, benefiting from per-share dynamics and underscoring underlying earnings strength despite the tax headwind.